ATE334965T1 - Piperidinverbindungen als muscarinantagonisten - Google Patents
Piperidinverbindungen als muscarinantagonistenInfo
- Publication number
- ATE334965T1 ATE334965T1 AT02778485T AT02778485T ATE334965T1 AT E334965 T1 ATE334965 T1 AT E334965T1 AT 02778485 T AT02778485 T AT 02778485T AT 02778485 T AT02778485 T AT 02778485T AT E334965 T1 ATE334965 T1 AT E334965T1
- Authority
- AT
- Austria
- Prior art keywords
- piperidine compounds
- compounds
- muscarine antagonists
- methods
- well
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32835601P | 2001-10-10 | 2001-10-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE334965T1 true ATE334965T1 (de) | 2006-08-15 |
Family
ID=23280651
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02778485T ATE334965T1 (de) | 2001-10-10 | 2002-10-08 | Piperidinverbindungen als muscarinantagonisten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6831089B2 (de) |
| EP (1) | EP1434766B1 (de) |
| JP (2) | JP2005506339A (de) |
| CN (1) | CN1301972C (de) |
| AT (1) | ATE334965T1 (de) |
| CA (1) | CA2462861A1 (de) |
| DE (1) | DE60213629T2 (de) |
| ES (1) | ES2269774T3 (de) |
| MX (1) | MXPA04003298A (de) |
| WO (1) | WO2003031412A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7700603B2 (en) | 2003-12-15 | 2010-04-20 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7763609B2 (en) | 2003-12-15 | 2010-07-27 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| US7592348B2 (en) | 2003-12-15 | 2009-09-22 | Schering Corporation | Heterocyclic aspartyl protease inhibitors |
| ATE489370T1 (de) | 2005-06-14 | 2010-12-15 | Schering Corp | Herstellung und verwendung von verbindungen als aspartylproteasehemmer |
| WO2006138264A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Aspartyl protease inhibitors |
| EP1891021B1 (de) | 2005-06-14 | 2019-01-23 | Merck Sharp & Dohme Corp. | Aspartylproteasehemmer |
| CN101193892A (zh) | 2005-06-14 | 2008-06-04 | 先灵公司 | 大环杂环天冬氨酰基蛋白酶抑制剂 |
| WO2006138265A2 (en) | 2005-06-14 | 2006-12-28 | Schering Corporation | Heterocyclic aspartyl protease inhibitors, preparation and use thereof |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ブレインセルス，インコーポレイティド | ムスカリン性受容体調節による神経発生 |
| JP2010512389A (ja) | 2006-12-12 | 2010-04-22 | シェーリング コーポレイション | アスパルチルプロテアーゼ阻害剤 |
| WO2009032277A1 (en) | 2007-09-06 | 2009-03-12 | Schering Corporation | Gamma secretase modulators |
| EP2227471A1 (de) | 2007-12-11 | 2010-09-15 | Schering Corporation | Modulatoren von gamma-sekretase |
| AU2009314049B2 (en) | 2008-11-13 | 2015-03-05 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| TW201034666A (en) | 2008-12-22 | 2010-10-01 | Schering Corp | Gamma secretase modulators |
| AU2009330234A1 (en) | 2008-12-22 | 2011-07-07 | Merck Sharp & Dohme Corp. | Gamma secretase modulators |
| US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
| EP2443118A1 (de) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gammasekretasemodulatoren |
| EP2443121A2 (de) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gammasekretasemodulatoren |
| US20110281853A1 (en) | 2010-05-12 | 2011-11-17 | Rishi Arora | Compositions and methods for treating or preventing atrial fibrillation |
| GB201114448D0 (en) | 2011-08-22 | 2011-10-05 | Takeda Pharmaceutical | Compounds and their use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5889006A (en) * | 1995-02-23 | 1999-03-30 | Schering Corporation | Muscarinic antagonists |
| IL117149A0 (en) * | 1995-02-23 | 1996-06-18 | Schering Corp | Muscarinic antagonists |
| US6387930B1 (en) * | 1999-05-04 | 2002-05-14 | Schering Corporation | Piperidine derivatives useful as CCR5 antagonists |
| WO2001021590A1 (en) * | 1999-09-22 | 2001-03-29 | Schering Corporation | Muscarinic antagonists |
| US6294554B1 (en) * | 1999-09-22 | 2001-09-25 | Schering Corporation | Muscarinic antagonists |
-
2002
- 2002-10-08 EP EP02778485A patent/EP1434766B1/de not_active Expired - Lifetime
- 2002-10-08 MX MXPA04003298A patent/MXPA04003298A/es unknown
- 2002-10-08 ES ES02778485T patent/ES2269774T3/es not_active Expired - Lifetime
- 2002-10-08 DE DE60213629T patent/DE60213629T2/de not_active Expired - Lifetime
- 2002-10-08 AT AT02778485T patent/ATE334965T1/de not_active IP Right Cessation
- 2002-10-08 CA CA002462861A patent/CA2462861A1/en not_active Abandoned
- 2002-10-08 JP JP2003534396A patent/JP2005506339A/ja not_active Ceased
- 2002-10-08 CN CNB028199901A patent/CN1301972C/zh not_active Expired - Fee Related
- 2002-10-08 US US10/266,505 patent/US6831089B2/en not_active Expired - Fee Related
- 2002-10-08 WO PCT/US2002/032199 patent/WO2003031412A1/en active IP Right Grant
-
2009
- 2009-04-16 JP JP2009100409A patent/JP2009155350A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| ES2269774T3 (es) | 2007-04-01 |
| US20030207917A1 (en) | 2003-11-06 |
| WO2003031412A1 (en) | 2003-04-17 |
| EP1434766B1 (de) | 2006-08-02 |
| CA2462861A1 (en) | 2003-04-17 |
| DE60213629T2 (de) | 2007-10-18 |
| MXPA04003298A (es) | 2004-07-23 |
| CN1301972C (zh) | 2007-02-28 |
| DE60213629D1 (de) | 2006-09-14 |
| JP2009155350A (ja) | 2009-07-16 |
| US6831089B2 (en) | 2004-12-14 |
| JP2005506339A (ja) | 2005-03-03 |
| CN1568313A (zh) | 2005-01-19 |
| EP1434766A1 (de) | 2004-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE334965T1 (de) | Piperidinverbindungen als muscarinantagonisten | |
| ATE299494T1 (de) | Carbamat-derivate als muscarin-rezeptor antonisten | |
| MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
| DE60131967D1 (de) | Nr1h4-kern-rezeptor-bindende verbindungen | |
| DE60231341D1 (de) | Fluor- und sulfonylaminohaltige, 3,6-disubstituierptorantagonisten | |
| ATE382353T1 (de) | Substiuierte piperidine als melanocortinrezeptor- modulatoren | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| MY149422A (en) | 5-(arylsulfonyl)-pyrazolopiperidines | |
| WO2003028641A3 (en) | Mch receptor antagonists | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| WO2005090296A3 (en) | N-substituted benzene sulfonamides | |
| ATE466860T1 (de) | Cgrp-rezeptorantagonisten | |
| EA200501595A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| WO2004005262A3 (en) | New neuropeptide y y5 receptor antagonists | |
| EA200801302A1 (ru) | Композиции и способы лечения нарушений цнс | |
| ATE423100T1 (de) | Neue chinolinverbindungen, die dazu in der lage sind, sich an den cb2-rezeptor zu binden | |
| ATE383345T1 (de) | Quinoxalin-3-on-verdindungen als orexin-rezeptor antagonisten. | |
| ATE396969T1 (de) | 3,6-disubstituierte azabicyclo (3.1.0)hexanderivate, die sich als muscarinrezeptorantagonisten eignen | |
| EA200501593A1 (ru) | Азабициклические производные в качестве антагонистов мускаринового рецептора | |
| BR0211140A (pt) | Compostos e composições de indóis de hexaidroazepina (4, 5-g) e indolinas como ligantes de receptores 5-ht | |
| DE60327375D1 (de) | Arylindenopyridin- und arylindenopyrimidinverbindungen und ihre verwendung als adenosin-a2a-rezeptor antagonisten | |
| ATE282041T1 (de) | Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist | |
| ATE362364T1 (de) | Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten | |
| ATE486078T1 (de) | 5,6-disubstituierte oxadiazolopyrazine und thiadiazolopyrazine als liganden des cxc- chemokinrezeptors | |
| MXPA05012572A (es) | Derivado de 5-h-benzo[d]naft[2,1-b]azepina como antagonistas selectivos del receptor d1/d5 para el tratamiento de la obesidad y trastornos del sistema nervioso central. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |